The Hydroxyurea Kalbefarma from PT Kalbe Farma Tbk - steady oral support for chronic myelogenous leukemia

Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-28, 04:38. Details in the imprint.

The Hydroxyurea Kalbefarma capsule sits in a small blister strip, white and unremarkable, yet for many leukemia patients in Indonesia it is a quiet daily ritual that keeps blood counts under control and clinic visits more predictable.

What Hydroxyurea Kalbefarma does

Hydroxyurea Kalbefarma from PT Kalbe Farma Tbk is an oral cytotoxic medicine based on hydroxyurea, used to treat chronic myelogenous leukemia and other myeloproliferative disorders by reducing excessive blood cell production. It is typically prescribed in capsule form for once-daily dosing under oncologist supervision.

Indonesian oncologist Dr. R.M. Daryono describes hydroxyurea as a practical backbone therapy, especially where access to newer targeted medicines remains limited, because it can be titrated according to blood counts and tolerated for years with consistent monitoring.

How it is taken in real life

A typical Hydroxyurea Kalbefarma capsule is swallowed with water after a simple meal, the hard shell smooth against the fingers as the patient tips it from the foil, often alongside folic acid or other supportive medicines as part of a fixed morning routine at home.

Dosing is individualized, often starting at around 15 mg per kilogram body weight per day, then adjusted based on complete blood count results and clinical response to avoid excessive lowering of white cells, platelets, or hemoglobin over time.

Strengths of the capsule format

For many patients at Jakarta's Dharmais Cancer Hospital, Hydroxyurea Kalbefarma is valued for its oral simplicity compared with older injectable chemotherapies, allowing them to work or care for family while returning to the clinic mainly for lab checks.

The capsule format also facilitates flexible dose adjustments by the treating hematologist, who can increase or decrease the daily amount or introduce dose breaks when neutrophil counts approach lower safety thresholds, without changing the underlying therapy concept.

Where caution is needed

Side effects with Hydroxyurea Kalbefarma are closely linked to its impact on fast-dividing cells, so oncologists like Dr. Daryono warn patients about potential mouth sores, skin changes, and infection risk if white blood cells are suppressed too far for too long.

Regular complete blood counts, typically every few weeks in the first months and then spaced out once stable, remain mandatory, and treatment interruptions or dose reductions are common tools to keep toxicity within acceptable ranges for long-term use.

Place in Kalbe's wider oncology line

Hydroxyurea Kalbefarma sits alongside other prescription cancer medicines in Kalbe Farma's portfolio, including supportive care products and newer targeted agents introduced through licensing and joint ventures, giving Indonesian oncologists more layered treatment options.

Chief executive officer Vidjongtius has repeatedly highlighted oncology and chronic-disease management as strategic focus areas for Kalbe, where established products like hydroxyurea provide steady volume while the company invests in more advanced therapies over time.

Context and Kalbe Farma shares

Overall, Hydroxyurea Kalbefarma exemplifies how a long-serving oral cytotoxic medicine still plays a role in everyday cancer care in Indonesia, even as newer tyrosine kinase inhibitors and immunotherapies expand the therapeutic landscape.

PT Kalbe Farma Tbk shares (ISIN ID1000096605) are listed on the Indonesia Stock Exchange in Jakarta; the PT Kalbe Farma Tbk share price is reported in Indonesian rupiah and reflects the company's combined prescription, consumer health, and nutritional businesses.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.